Abstract 11P
Background
Breast cancer is the second leading cause of cancer deaths in women worldwide. Early detection of breast cancer has been demonstrated to improve patients' treatment outcomes and survival. Liquid biopsy based on detecting DNA shed by breast tumors into the circulation, known as circulating tumor DNA (ctDNA), has emerged as a promising non-invasive approach. However, differentiating benign breast lumps from malignant tumors remains a challenge in current clinical practice, and inaccurate detection may result in unnecessary invasive procedures.
Methods
To address this challenge, we employed a multimodal analysis approach, namely SPOT-MAS (Screen for the Presence of Tumor by DNA Methylation and Size) to profile alterations in methylation and fragment length patterns of cell free DNA (cfDNA) from 133 breast cancer patients and 59 patients with benign breast lumps comprising cysts and fibroadenomas.
Results
We identified multiple distinct end motifs, differential methylation and fragment length patterns across 22 chromosomes, which were further exploited as input features to build machine learning models to discriminate early-stage breast cancer patients from patients with benign lesions. The models achieved an area under the curve of 0.87 (95% CI: 0.79 – 0.94) and a sensitivity of 64.1% at 90% specificity in detecting patients with malignant tumors.
Conclusions
Therefore, our findings demonstrated that cancer-specific methylation and fragmentomic patterns in plasma cfDNA could serve as novel biomarkers for accurately differentiating malignant breast cancer patients from those with benign lesions.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Medical Genetics Institute and Gene Solutions Joint Stock Company, Vietnam.
Funding
Gene Solutions Joint Stock Company.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
204P - A radiomics strategy based on CT intra-tumoral and peritumoral regions for preoperative prediction of neoadjuvant chemoradiotherapy for esophageal cancer
Presenter: zhiyang li
Session: Poster Display
Resources:
Abstract
205TiP - IMPACT: Randomized, multicenter, phase III study evaluating the efficacy of immunotherapy (atezolizumab) plus anti-VEGF therapy (bevacizumab) in combination with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma (HCC)
Presenter: Tatsuya Yamashita
Session: Poster Display
Resources:
Abstract
206TiP - SIERRA: A phase IIIb, single-arm, multicentre study of tremelimumab plus durvalumab for first-line treatment of advanced unresectable hepatocellular carcinoma
Presenter: Stephen Chan
Session: Poster Display
Resources:
Abstract
207TiP - A two-arm randomized open-label prospective design superiority phase III clinical trial to compare the efficacy of docetaxel-oxaliplatin-capecitabine/ 5 -fluorouracil (DOC/F) followed by docetaxel versus CAPOX/mFOLFOX-7 in advanced gastric cancers
Presenter: Prabhat Bhargava
Session: Poster Display
Resources:
Abstract
212P - Mutational landscape and characteristics of ERBB2 in urothelial carcinoma
Presenter: Mingwei Li
Session: Poster Display
Resources:
Abstract
213P - Prognostic significance of absolute lymphocyte count in patients with metastatic renal cell carcinoma treated with first-line combination immunotherapies: Results from the International metastatic renal cell carcinoma database consortium (IMDC)
Presenter: Kosuke Takemura
Session: Poster Display
Resources:
Abstract
214P - Development and prospective validation of a multiplex RNA urine test for noninvasive detection and surveillance of urothelial carcinoma
Presenter: Hua Xu
Session: Poster Display
Resources:
Abstract
215P - Real-world outcomes of first-line tislelizumab plus axitinib in patients with metastatic non-clear cell renal cell carcinoma (mnccRCC)
Presenter: Pei Dong
Session: Poster Display
Resources:
Abstract
216P - Preliminary efficacy and safety results from ‘ReBirth’: A phase II study of risk-based bladder-sparing therapy for MIBC
Presenter: Yijun Shen
Session: Poster Display
Resources:
Abstract
217P - Conditional reprogramming of urine-derived bladder cancer cells: A model for precision medicine
Presenter: Yu Dong
Session: Poster Display
Resources:
Abstract